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a,b,c Saudi Arabian response to the letter by Professor Sim Sai Tin,I we agree that the clinical usefulness of NT-
proBNP has been widely discussed. Dr. Sim Sai
Tin mentions the report by Ranjith et al. [1] on
the usefulness of this biomarker in which the
authors suggest that ‘‘NT-proBNP should be
included in the risk assessment of ACS to provide
guidance for further therapeutic strategies’’. I
would first like to state that the discussion of
related subjects from various centers is mandatory
and that multiple perspectives and the study of
diverse demographics add to the enrichment of
medical knowledge. Furthermore, our study was
different to the one conducted by Ranjith et al.
in several ways. First, our study populations were
dissimilar. Our patients comprised those with
unstable angina (48.48%; 64 patients) and
NSTEMI (34.8%; 46 patients) while patients with
STEMI represented only 16.6% (22 patients). On
the other hand, most of the patients in the study
by Ranjith et al. had STEMI (71%; 142 patients).
Second, we performed serial assessments of NT-
proBNP on admission and after cardiac catheteri-
zation; while Ranjith et al. assessed NT-proBNP
only on admission. Third, coronary angiography
was conducted on all patients in our study andwe assessed the severity of coronary artery lesion,
while Ranjith et al. conducted the same on only a
small percentage (21% of his patients). And
finally, most of our patients were treated by revas-
cularization either by percutaneous coronary
intervention (PCI) or surgical revascularization in
addition to medical treatment, while the patients
in the study by Ranjith et al. were treated medi-
cally in most cases, with cardiac catheterization
performed on only 21% of their patients. Finally,
our study concluded that NT-proBNP is not only
a prognostic marker for complications and poor
prognosis in acute coronary syndrome, but that
it can also predict the severity of coronary artery
stenosis and the number of vessels affected [2].
Written by Abdelhakem Selem Elsayed.
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